FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma

[FDA]

On October 21, 2022, the Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC).


Baca selengkapnya di : http://www.fda.gov...